Pure Global

Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal - Trial NCT01915108

Access comprehensive clinical trial information for NCT01915108 through Pure Global AI's free database. This phase not specified trial is sponsored by Sangjin Park and is currently Completed. The study focuses on Respiratory Complication. Target enrollment is 128 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT01915108
Completed
drug
Trial Details
ClinicalTrials.gov • NCT01915108
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal
Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal During Emergence From Sevoflurane-remifentanil Anesthesia

Study Focus

Respiratory Complication

Remifentanil

Interventional

drug

Sponsor & Location

Sangjin Park

Yeungnam University College of Medicine

Timeline & Enrollment

N/A

Jul 01, 2012

Jun 01, 2013

128 participants

Primary Outcome

Number of Patients With Adverse Events Following LMA Removal

Summary

This study was designed to determine the optimal dose of remifentanil that can prevent the
 complications associated with the removal of LMA without delaying emergence.

ICD-10 Classifications

Respiratory disorder, unspecified
Other respiratory disorders
Respiratory failure, unspecified
Other postprocedural respiratory disorders
Other specified respiratory disorders

Data Source

ClinicalTrials.gov

NCT01915108

Non-Device Trial